| Attributes | Values |
|---|
| rdf:type
| |
| description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- article scientifique (fr)
- artículu científicu espublizáu en 2010 (ast)
- наукова стаття, опублікована в березні 2010 (uk)
- مقالة علمية نشرت في 09 مارس 2010 (ar)
- scientific article published on 09 March 2010 (en)
|
| publication date
| |
| publication date
| |
| exact match
| |
| exact match
| |
| cites work
| |
| cites work
| |
| author name string
| |
| author name string
| - Irvin M Modlin
- Steven F Moss
- Mark Kidd
- Bjorn I Gustafsson
- Apostolos V Tsolakis
- Marianne Pavel
|
| rdfs:label
| - Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (en)
- Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (nl)
- Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (ast)
|
| skos:prefLabel
| - Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (en)
- Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (nl)
- Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (ast)
|
| name
| - Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (en)
- Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (nl)
- Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (ast)
|
| title
| |
| title
| - Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| - 10.1245/S10434-010-1006-3
|
| ResearchGate publication ID
| |
| ResearchGate publication ID
| |
| Dimensions Publication ID
| |
| Dimensions Publication ID
| |
| is about
of | |
| is cites work
of | - The stimulatory adenosine receptor ADORA2B regulates serotonin (5-HT) synthesis and release in oxygen-depleted EC cells in inflammatory bowel disease
- Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors
- The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors
- Neuroendocrine phenotype alteration and growth suppression through apoptosis by MK-2206, an allosteric inhibitor of AKT, in carcinoid cell lines in vitro
- ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary
- ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.
- Glucagonoma-induced acute heart failure
- Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view
- Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies
- Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine
- Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?
- The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood
- Development of type I gastric carcinoid in patients with chronic atrophic gastritis.
- The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms
- Proteins with altered levels in plasma from glioblastoma patients as revealed by iTRAQ-based quantitative proteomic analysis
- Diagnosis of Zollinger-Ellison syndrome: increasingly difficult
- Effect of proton-pump inhibitor therapy on serum chromogranin a level.
- Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors?
- Serum pancreastatin: the next predictive neuroendocrine tumor marker
- Recommendations for management of patients with neuroendocrine liver metastases
- Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)